Phase II study of combination chemotherapy of gemcitabine, TS-1 and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.
Not Applicable
- Conditions
- nresectable advanced pancreatic cancer
- Registration Number
- JPRN-UMIN000006161
- Lead Sponsor
- Jikei University school of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)Pulmonary fibrosis or interstitial pneumonitis 2)Active bacterial or fungal infection 3)Uncontrollable heart disease 4)Uncontrollable DM 5)Pregnant or lactating women or women fo childearing potential, and men who want to get partner pregnat 6)Severe drug allergy 7)Simultaneous or metachronous double cancers 8)uncontrollable ascites
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method